泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301263 泰恩康

交易中 11-27 13:48:57

{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":14.12,"timestamp":1732686537000,"preClose":13.75,"halted":0,"volume":4458168,"delay":0,"floatShares":263000000,"shares":425000000,"eps":0.3167,"marketStatus":"交易中","marketStatusCode":2,"change":0.37,"latestTime":"11-27 13:48:57","open":13.83,"high":14.32,"low":13.57,"amount":62032800,"amplitude":0.0545,"askPrice":14.12,"askSize":1,"bidPrice":14.11,"bidSize":16,"shortable":0,"etf":0,"ttmEps":0.3167,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732690800000},"adr":0,"adjPreClose":13.75,"symbolType":"stock","openAndCloseTimeList":[[1732671000000,1732678200000],[1732683600000,1732690800000]],"highLimit":15.13,"lowLimit":12.38,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":425497500,"pbRate":3.3,"roa":"--","roe":"6.49%","epsLYR":0.38,"committee":0.541538,"marketValue":6008000000,"floatMarketCap":3713000000,"peRate":44.584779,"changeRate":0.0269,"turnoverRate":0.017,"status":0},"requestUrl":"/m/hq/s/301263/wiki","defaultTab":"wiki","newsList":[{"id":"2485239151","title":"11月22日泰恩康发生1笔大宗交易 成交金额330.19万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485239151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485239151?lang=zh_cn&edition=full","pubTime":"2024-11-22 17:11","pubTimestamp":1732266664,"startTime":"0","endTime":"0","summary":"证券之星消息，11月22日泰恩康发生大宗交易，交易数据如下：大宗交易成交价格12.39元，相对当日收盘价折价9.23%，成交26.65万股，成交金额330.19万元，买方营业部为中航证券有限公司深圳海德三道证券营业部，卖方营业部为渤海证券股份有限公司天津水上公园东路证券营业部。近三个月该股共发生1笔大宗交易，合计成交2665.0手，折价成交1笔。截至2024年11月22日收盘，泰恩康报收于13.65元，下跌4.14%，换手率1.59%，成交量4.19万手，成交额5830.78万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200027679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2485280676","title":"泰恩康(301263.SZ)子公司收到复方硫酸钠片药品注册受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2485280676","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485280676?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:58","pubTimestamp":1732262303,"startTime":"0","endTime":"0","summary":"复方硫酸钠片最早由美国FDA于2020年11月批准的一种新型口服固体片剂肠道清洁剂，作用机制是硫酸钠和硫酸镁的渗透作用产生导泻作用，用于成人结肠镜检查前的肠道准备工作。国内目前常见的肠道准备药物为复方聚乙二醇电解质，因口服液体量大、口味较差，患者易出现胃肠道不良反应。截至公告披露日，经查询国家药监局网站，国内尚未有其他企业取得复方硫酸钠片的药品注册证书，华铂凯盛为首个申报该药品注册上市的企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2484958477","title":"泰恩康：刘文华、亿鑫投资等多家机构于11月15日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2484958477","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484958477?lang=zh_cn&edition=full","pubTime":"2024-11-19 09:33","pubTimestamp":1731980025,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月18日泰恩康发布公告称刘文华、亿鑫投资、金信基金、时代伯乐创业投资、国元证券、红荔湾投资、招商证券、证券时报于2024年11月15日调研我司。2024 年 9 月，公司自主研发“爱廷”系列又一男科重点产品的爱廷达正式上市销售。公司预计将于 2025 年二季度公布临床 II 期数据，后续若获批上市后有望成为公司的重磅品种，为公司创造新的利润增长点。该股最近90天内共有2家机构给出评级，买入评级2家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900008811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2484017939","title":"【机构调研记录】金信基金调研泰恩康","url":"https://stock-news.laohu8.com/highlight/detail?id=2484017939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484017939?lang=zh_cn&edition=full","pubTime":"2024-11-19 08:04","pubTimestamp":1731974673,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月18日披露的机构调研信息，金信基金近期对1家上市公司进行了调研，相关名单如下：1）泰恩康 个股亮点：?以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900006755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2481294536","title":"华安证券：给予泰恩康买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481294536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481294536?lang=zh_cn&edition=full","pubTime":"2024-11-06 16:50","pubTimestamp":1730883046,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超,李昌幸,刘洪飞近期对泰恩康进行研究并发布了研究报告《Q3业绩符合预期，CKBAII期全部受试者入组》，本报告对泰恩康给出买入评级，当前股价为14.98元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有2家机构给出评级，买入评级2家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600028053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600909","301263"],"gpt_icon":0},{"id":"2481465693","title":"泰恩康（301263）11月5日主力资金净卖出897.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481465693","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481465693?lang=zh_cn&edition=full","pubTime":"2024-11-06 09:21","pubTimestamp":1730856118,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月5日收盘，泰恩康报收于14.71元，上涨0.14%，换手率4.51%，成交量11.85万手，成交额1.73亿元。近5日资金流向一览见下表：泰恩康融资融券信息显示，融资方面，当日融资买入2437.05万元，融资偿还2049.65万元，融资净买入387.4万元。泰恩康主营业务：代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600009117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2479032207","title":"泰恩康最新公告：CKBA软膏II期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2479032207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479032207?lang=zh_cn&edition=full","pubTime":"2024-10-31 18:21","pubTimestamp":1730370066,"startTime":"0","endTime":"0","summary":"泰恩康公告，公司控股子公司博创园组织开展的用于治疗白癜风适应症的1类创新药物CKBA软膏已按照II期临床方案完成全部受试者的入组。截至公告披露日，CKBA软膏II期临床已完成全部200例受试者入组，整体安全性良好，盲态数据下已体现出较好疗效趋势。公司将加快推进CKBA软膏白癜风适应症II期临床试验进度，并计划提交突破性疗法认定申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100037906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK1583","BK0250","BK1141","BK1576","03347"],"gpt_icon":0},{"id":"2479703950","title":"泰恩康(301263.SZ)：CKBA软膏II期临床方案完成受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2479703950","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479703950?lang=zh_cn&edition=full","pubTime":"2024-10-31 18:17","pubTimestamp":1730369856,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司控股子公司江苏博创园生物医药科技有限公司(简称“博创园”)组织开展的用于治疗白癜风适应症的1类创新药物CKBA软膏已按照II期临床方案完成全部受试者的入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1205004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2479261239","title":"泰恩康（301263）2024年三季报简析：净利润减17.97%，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479261239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479261239?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:36","pubTimestamp":1730241378,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泰恩康发布2024年三季报。截至本报告期末，公司营业总收入5.72亿元，同比下降1.5%，归母净利润1.16亿元，同比下降17.97%。按单季度数据看，第三季度营业总收入1.77亿元，同比上升0.53%，第三季度归母净利润3058.66万元，同比下降6.66%。本报告期泰恩康应收账款上升，应收账款同比增幅达33.43%。去年的净利率为20.18%，算上全部成本后，公司产品或服务的附加值高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000007462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263"],"gpt_icon":0},{"id":"2479194420","title":"泰恩康(301263)9月30日股东户数1.31万户，较上期增加7.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479194420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479194420?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:21","pubTimestamp":1730193703,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泰恩康披露，截至2024年9月30日公司股东户数为1.31万户，较8月9日增加914.0户，增幅为7.52%。在化学制药行业个股中，泰恩康股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.11万户。从股价来看，2024年8月9日至2024年9月30日，泰恩康区间涨幅为6.93%，在此期间股东户数增加914.0户，增幅为7.52%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900031820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2475320615","title":"泰恩康（301263）10月14日主力资金净卖出721.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2475320615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475320615?lang=zh_cn&edition=full","pubTime":"2024-10-15 09:28","pubTimestamp":1728955689,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月14日收盘，泰恩康报收于13.92元，上涨0.58%，换手率1.86%，成交量4.9万手，成交额6745.54万元。近5日资金流向一览见下表：泰恩康融资融券信息显示，融资方面，当日融资买入798.48万元，融资偿还799.58万元，融资净偿还1.1万元。泰恩康主营业务：代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101500007861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2473584441","title":"泰恩康涨5.48%，华安证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2473584441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473584441?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:55","pubTimestamp":1728381356,"startTime":"0","endTime":"0","summary":"今日泰恩康涨5.48%，收盘报15.79元。2024年8月30日，华安证券研究员谭国超,李昌幸发布了对泰恩康的研报《核心产品优势稳固，CKBAII期临床试验顺利》，该研报对泰恩康给出“买入”评级。维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为华安证券的李昌幸、谭国超。泰恩康个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800027163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600909","301263"],"gpt_icon":0},{"id":"2471988808","title":"泰恩康涨11.05%，华安证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2471988808","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471988808?lang=zh_cn&edition=full","pubTime":"2024-09-30 18:44","pubTimestamp":1727693094,"startTime":"0","endTime":"0","summary":"今日泰恩康涨11.05%，收盘报14.97元。2024年8月30日，华安证券研究员谭国超,李昌幸发布了对泰恩康的研报《核心产品优势稳固，CKBAII期临床试验顺利》，该研报对泰恩康给出“买入”评级。维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为华安证券的李昌幸、谭国超。泰恩康个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000033436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","600909"],"gpt_icon":0},{"id":"2469917225","title":"【ESG动态】泰恩康（301263.SZ）华证指数ESG最新评级CCC，行业排名第13","url":"https://stock-news.laohu8.com/highlight/detail?id=2469917225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469917225?lang=zh_cn&edition=full","pubTime":"2024-09-22 09:08","pubTimestamp":1726967308,"startTime":"0","endTime":"0","summary":"日前，华证指数公布了新一期的ESG评级结果，泰恩康获得CCC评级，上一期ESG评级为B。本期ESG评级在26家医疗保健提供商与服务行业A股上市公司中排名第13。证券之星成立ESG生态联盟，旨在为上市公司和投资机构、ESG研究与评级机构等搭建沟通与交流平台，推动形成具有中国特色、国际认同的ESG管理体系。ESG 指标分别从环境、社会以及公司治理角度，来衡量企业发展的可持续性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092200000712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","159717"],"gpt_icon":0},{"id":"2468370341","title":"泰恩康(301263.SZ)：子公司枸橼酸西地那非片、布瑞哌唑片上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2468370341","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468370341?lang=zh_cn&edition=full","pubTime":"2024-09-18 16:56","pubTimestamp":1726649814,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康 公告，公司全资子公司安徽泰恩康制药有限公司于近日收到国家药品监督管理局签发的枸橼酸西地那非片及布瑞哌唑片境内生产药品注册上市许可申请《受理通知书》，国家药监局对上述药品的药品注册上市许可申请进行了审查，决定予以受理。米内网数据显示，布瑞哌唑在2023年全球销售额突破20亿美元，同比增长超过20%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1184100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2468637018","title":"泰恩康最新公告：全资子公司药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2468637018","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468637018?lang=zh_cn&edition=full","pubTime":"2024-09-18 16:55","pubTimestamp":1726649740,"startTime":"0","endTime":"0","summary":"泰恩康公告，全资子公司安徽泰恩康制药有限公司近日收到国家药监局签发的枸橼酸西地那非片及布瑞哌唑片境内生产药品注册上市许可申请《受理通知书》。枸橼酸西地那非片用于ED，布瑞哌唑片用于治疗精神分裂症。国家药监局已对申请进行审查并决定受理。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091800023917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2468720553","title":"泰恩康：全资子公司药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2468720553","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468720553?lang=zh_cn&edition=full","pubTime":"2024-09-18 16:43","pubTimestamp":1726648983,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["01477","BK4588","BK4585","BK1574","LU0170899867.USD","ED","BK1191","BK4208","BK0250","LU2346227817.USD","301263"],"gpt_icon":0},{"id":"2466222361","title":"泰恩康：9月12日接受机构调研，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2466222361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466222361?lang=zh_cn&edition=full","pubTime":"2024-09-12 18:05","pubTimestamp":1726135528,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年9月12日泰恩康发布公告称公司于2024年9月12日接受机构调研。泰恩康2024年中报显示，公司主营收入3.95亿元，同比下降2.39%；归母净利润8574.89万元，同比下降21.37%；扣非净利润8438.53万元，同比下降16.84%；其中2024年第二季度，公司单季度主营收入2.06亿元，同比下降2.36%；单季度归母净利润4028.11万元，同比下降29.41%；单季度扣非净利润4094.75万元，同比下降25.09%；负债率20.99%，投资收益193.18万元，财务费用293.3万元，毛利率61.63%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091200030008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2466159699","title":"泰恩康(301263.SZ)：“比拉斯汀片”上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2466159699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466159699?lang=zh_cn&edition=full","pubTime":"2024-09-09 17:08","pubTimestamp":1725872890,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司全资子公司安徽泰恩康制药有限公司于近日收到国家药品监督管理局(“国家药监局”)签发的比拉斯汀片境内生产药品注册上市许可申请《受理通知书》，国家药监局对上述药品的药品注册上市许可申请进行了审查，决定予以受理。据悉，比拉斯汀(Bilastine)是第二代抗组胺药物，原研药由西班牙FAES制药公司开发，最早于2010年获准在欧盟上市销售，2023年获准在国内上市，用于治疗成人和12岁以上青少年的荨麻疹和变应性鼻炎。单次给药后，比拉斯汀会持续24小时抑制组胺诱导产生皮肤红肿及疱疹反应，安全性较高。截至目前比拉斯汀片在国内仅有原研药获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1180816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2466562061","title":"泰恩康最新公告：全资子公司收到药品注册受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2466562061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466562061?lang=zh_cn&edition=full","pubTime":"2024-09-09 16:58","pubTimestamp":1725872305,"startTime":"0","endTime":"0","summary":"泰恩康公告，公司全资子公司安徽泰恩康制药有限公司于近日收到国家药监局签发的比拉斯汀片境内生产药品注册上市许可申请《受理通知书》，国家药监局对上述药品的药品注册上市许可申请进行了审查，决定予以受理。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090900021601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","stockEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":-0.0317},{"period":"3month","weight":0.0401},{"period":"6month","weight":0.0088},{"period":"1year","weight":-0.2293},{"period":"ytd","weight":-0.1406}],"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","perCapita":"20134股","boardName":"批发业","registeredCapital":"42549万元","compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0121},{"period":"3month","weight":0.1488},{"period":"6month","weight":0.0544},{"period":"1year","weight":0.0752},{"period":"ytd","weight":0.0957}],"survey":"　　广东泰恩康医药股份有限公司主营业务为代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品包括处方药、OTC、医疗器械、卫生材料、医药技术服务等。","serverTime":1732686542120,"listedPrice":19.93,"stockholders":"13061人(较上一季度增加7.52%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}